| Atorvastatin Metabolite Measurements as a Diagnostic Tool for Statin-Induced Myopathy. | |
| | |
MedLine Citation:
|
PMID: 21815705 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Background: Myopathic complaints are common in the general population and are more frequent with increasing age. When myopathic symptoms arise in a patient treated with a HMG-CoA reductase inhibitor (statin), it is always a question of whether the symptoms are due to statin-induced myopathy (SIM) or not (non-SIM). Diagnosis of SIM is not as straightforward as previously thought, because the most commonly used biomarker, serum creatine kinase, shows low specificity and selectivity, except in serious cases of rhabdomyolysis. There is a definite need for a novel biomarker for SIM. Objective: Based on a previous study reporting an altered metabolic profile with increased systemic exposure to the suspected muscle-toxic metabolite atorvastatin lactone in patients with SIM compared with healthy controls, this study aimed to explore the use of atorvastatin metabolite measurements to diagnose muscular complaints during statin treatment as being either SIM or non-SIM. Patients, Setting, and Study Design: Fifty-three patients with self-reported myopathic symptoms during atorvastatin treatment were recruited from our outpatient clinic. The symptoms were clinically evaluated as being SIM or non-SIM, on the basis of atorvastatin re-challenge testing. Atorvastatin and its metabolites were measured at steady state in all patients and compared with the clinical evaluation to see if this could predict the outcome and hence be suitable as a diagnostic tool for SIM. Main Outcome Measure: This was an exploratory study to investigate the proportion of patients correctly diagnosed by different metabolite cut-off ratios. Results: With a cut-off ratio set at 1.1 for the atorvastatin lactone to atorvastatin acid ratio, 15 of 28 SIM patients (sensitivity of 54%) and 20 of 24 non-SIM patients (specificity of 83%) were correctly diagnosed. This corresponds to a positive predictive value of 79% and a negative predictive value of 61% (p = 0.006). Conclusion: The present study confirms an altered metabolic pattern of atorvastatin in patients with SIM and substantiates a central role of the lactone forms of statins in future investigations of statin myotoxicity. The atorvastatin lactone to acid ratio seems to be a valuable supportive diagnostic tool with high specificity and moderate sensitivity, adding to ordinary clinical evaluations when diagnosing SIM. Trial registration number (clinicaltrials.gov): NCT00414531. |
| | |
Authors:
|
Ine B Skottheim; Martin P Bogsrud; Monica Hermann; Kjetil Retterstøl; Anders Asberg |
Related Documents
:
|
3126305 - Factors influencing energy expenditure in patients with burns. 10507595 - The patient-related costs of care for sepsis patients in a united kingdom adult general... 19464975 - Matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with ... 8213865 - Ehrlichiosis presenting as a life-threatening illness with features of the toxic shock ... 20674205 - Coronary dual source multi detector computed tomography in patients suspected of corona... 14655195 - Cost analysis of renal replacement therapies in finland. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-8-4 |
Journal Detail:
|
Title: Molecular diagnosis & therapy Volume: - ISSN: 1177-1062 ISO Abbreviation: - Publication Date: 2011 Aug |
Date Detail:
|
Created Date: 2011-8-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101264260 Medline TA: Mol Diagn Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
School of Pharmacy, University of Oslo, Oslo, Norway. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Receptor Kinase Inhibitors Target NSCLC†: Two Antibodies and a Small-Molecule MET Inhibitor.
Next Document: Societal Values in the Allocation of Healthcare Resources: Is it All About the Health Gain?